Scalar Gauge Management LLC Has $1.71 Million Holdings in Cellebrite DI Ltd. $CLBT

Scalar Gauge Management LLC trimmed its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 30.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 92,210 shares of the company’s stock after selling 40,000 shares during the quarter. Cellebrite DI makes up about 0.9% of Scalar Gauge Management LLC’s investment portfolio, making the stock its 25th largest holding. Scalar Gauge Management LLC’s holdings in Cellebrite DI were worth $1,709,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Voss Capital LP grew its position in Cellebrite DI by 34.0% in the second quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock worth $82,400,000 after acquiring an additional 1,306,398 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in Cellebrite DI by 17.1% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after buying an additional 570,000 shares during the last quarter. Invesco Ltd. lifted its position in shares of Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after buying an additional 209,473 shares during the last quarter. Pertento Partners LLP raised its position in shares of Cellebrite DI by 11.8% in the second quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock valued at $47,130,000 after purchasing an additional 309,988 shares during the period. Finally, Handelsbanken Fonder AB lifted its stake in shares of Cellebrite DI by 61.3% in the second quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock worth $39,200,000 after buying an additional 931,300 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CLBT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Bank of America raised their price objective on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen downgraded shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $16.56 on Tuesday. The business’s fifty day moving average price is $17.82 and its two-hundred day moving average price is $16.99. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of 53.42, a price-to-earnings-growth ratio of 2.21 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). The firm had revenue of $126.03 million during the quarter, compared to analyst estimates of $122.98 million. Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.14 EPS. Research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.